Invitae

Employees:
350
Market Cap:
$405.02 million
Revenue:
$25.03 million
Net Income:
$-100.7 million
NYSE:
NVTA
Invitae
Employees:
350
Market Cap:
$405.02 million
Revenue:
$25.03 million
Net Income:
$-100.7 million
NYSE:
NVTA

Mar 3, 7:27 PM

We believe genetic testing can play a central role in shortening the diagnostic odyssey. Early diagnosis can transform care especially in disorders affecting children. Invitaes Behind the Seizure program in partnership with BioMarin, a global biotechnology company specializing in rare and ultra-rare diseases, helps to promote early genetic testing in epilepsy. Genetic information may help patients and their providers with diagnosis, prognosis, and identifying opportunities and eligibility for clinical trial participation. The patient eligibility requirements are consistent with early symptoms of CLN2 disease, a form of Batten disease. BioMarin has partnered with Invitae as part of their commitment to the CLN2 community. To learn more, please visit https://www.invitae.com/en/behindtheseizure/

Feb 27, 9:33 PM

Feb 27, 9:33 PM

Feb 27, 9:33 PM

9

Invitae jobs